<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02936401</url>
  </required_header>
  <id_info>
    <org_study_id>5R01NR015223</org_study_id>
    <secondary_id>R01NR015223</secondary_id>
    <nct_id>NCT02936401</nct_id>
  </id_info>
  <brief_title>Mindfulness Based Stress Reduction for Older Adults With HIV Associated Neurocognitive Disorders</brief_title>
  <official_title>Interventions for Symptom Management in Older Patients With HAND</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Nursing Research (NINR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard School of Public Health (HSPH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Missouri, St. Louis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of Mindfulness Based Stress Reduction&#xD;
      (MBSR) to alleviate stress, anxiety, and depressive symptoms, and improve attention among&#xD;
      patients aged 60 or older who suffer from HIV-associated neurocognitive disorders (HAND) and&#xD;
      have maximized treatment options.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study addresses symptom management for patients aged 60 and older who are living with&#xD;
      HIV infection, are on combination antiretroviral therapy (cART) with suppressed viral loads,&#xD;
      and yet continue to experience behavioral and cognitive symptoms of HIV-associated&#xD;
      neurocognitive disorders (HAND). It is increasingly relevant that HAND persists despite cART,&#xD;
      impacting between 30-50% of elders living with HIV. Patients suffer symptoms that are&#xD;
      pervasive in their impact on everyday functioning and quality of life; yet these patients are&#xD;
      currently left with a dearth of treatment options. In this study, the investigators employ a&#xD;
      randomized controlled evaluation of Mindfulness Based Stress Reduction (MBSR) to target&#xD;
      attention, stress, anxiety, and depressive symptoms among patients who have HAND and have&#xD;
      maximized treatment options. The investigators will employ intrinsic connectivity network&#xD;
      (ICN) analyses of resting state functional magnetic resonance imaging to demonstrate&#xD;
      increased strength of brain networks corresponding to improved symptoms. The investigators&#xD;
      will quantify social networks and perceived strength of social networks to determine if they&#xD;
      moderate the main findings. Together this work employs geriatric, neuroscience and&#xD;
      complementary medicine disciplines to reduce the symptom burden in aging HIV-infected&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2015</start_date>
  <completion_date type="Actual">November 7, 2019</completion_date>
  <primary_completion_date type="Actual">November 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuous Performance Task</measure>
    <time_frame>48 weeks after enrollment</time_frame>
    <description>A neuropsychological test to assess attention and information processing and executive functioning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symbol-Digit modalities test</measure>
    <time_frame>48 weeks after enrollment</time_frame>
    <description>A neuropsychological test to assess executive functioning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Letter Number Sequencing</measure>
    <time_frame>48 weeks after enrollment</time_frame>
    <description>A neuropsychological test to assess executive functioning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Activities of Daily Living (ADL) &amp; Instrumental Activities of Daily Living (IADL) scales</measure>
    <time_frame>48 weeks after enrollment</time_frame>
    <description>Questionnaires to assess everyday function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived Stress Scale</measure>
    <time_frame>48 weeks after enrollment</time_frame>
    <description>Questionnaire to assess stress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>State-Trait Anxiety Inventory</measure>
    <time_frame>48 weeks after enrollment</time_frame>
    <description>Questionnaire to assess anxiety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geriatric Depression Scale</measure>
    <time_frame>48 weeks after enrollment</time_frame>
    <description>Questionnaire to assess depression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Buss-Durkee Irritability subscale</measure>
    <time_frame>48 weeks after enrollment</time_frame>
    <description>Questionnaire to assess irritability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Center for Neurological Study - Lability Scale</measure>
    <time_frame>48 weeks after enrollment</time_frame>
    <description>Questionnaire to assess affective lability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Affective Intensity Measure</measure>
    <time_frame>48 weeks after enrollment</time_frame>
    <description>Questionnaire to assess euphoria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>World Health Organization Quality of Life - HIV Scale</measure>
    <time_frame>48 weeks after enrollment</time_frame>
    <description>Questionnaire to assess quality of life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Connectivity of the default mode network (DMN) as determined by analysis of resting state functional magnetic resonance imaging</measure>
    <time_frame>16 weeks after enrollment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Connectivity of the salience network (SAL) as determined by analysis of resting state functional magnetic resonance imaging</measure>
    <time_frame>16 weeks after enrollment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Impaired Cognition</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>MBSR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm enter the 8-week MBSR course immediately after the baseline visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the waitlist control arm will receive standard of care for 16 weeks after the baseline visit, and then will be offered an identical 8-week MBSR course.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MBSR</intervention_name>
    <description>Mindfulness Based Stress Reduction (MBSR) is a standardized 8 week course taught by trained instructors.</description>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_label>MBSR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 55 years&#xD;
&#xD;
          -  HIV-infected. For cases in which a participant has an undetectable plasma viral load&#xD;
             and is not currently on cART, the participant will be asked to complete HIV antibody&#xD;
             testing.&#xD;
&#xD;
          -  Undetectable plasma viral load&#xD;
&#xD;
          -  Symptomatic and sufficient neuropsychological testing abnormality to be rated as&#xD;
             having impairment by consensus conference, but deficits in everyday functioning that&#xD;
             would rate them as having no more than moderate disease. Participants with severe&#xD;
             deficits consistent with dementia will not be randomized unless the study team agrees&#xD;
             that deficits are mild enough to withstand rigors of MBSR.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 55 years&#xD;
&#xD;
          -  Failure to attend screening visits after two attempts and despite support offered&#xD;
&#xD;
          -  Unwilling to participate in 8-week intervention&#xD;
&#xD;
          -  Endorsing illicit drug use in the past 6 months&#xD;
&#xD;
          -  Current or extensive previous mindfulness practitioner&#xD;
&#xD;
          -  Detectable plasma HIV RNA (VL) in the previous 6 months or at enrollment. Individuals&#xD;
             with VL &lt;500 copies will be allowed to enroll if they have a history of UD VL with&#xD;
             unchanged cART and show documentation of their past two clinical VL at UD levels (so&#xD;
             called &quot;viral blips&quot;).&#xD;
&#xD;
          -  Any treatable condition that may impact cognition, including:&#xD;
&#xD;
               -  Neurosyphilis (cases with serum RPR positive will undergo lumbar puncture to&#xD;
                  evaluate)&#xD;
&#xD;
               -  Thyroid disorders (untreated)&#xD;
&#xD;
               -  B12 deficiency (untreated)&#xD;
&#xD;
               -  Cancer (requiring chemotherapy)&#xD;
&#xD;
               -  Neurological or psychiatric conditions where treatment options exist, such as&#xD;
                  multiple sclerosis, schizophrenia, uncontrolled epilepsy, recent and untreated&#xD;
                  major depression&#xD;
&#xD;
               -  HIV CNS escape (lumbar punctures will be completed in cases with clinical&#xD;
                  scenarios worrisome for escape as done clinically; e.g. more rapid course, new&#xD;
                  neurological symptoms, recent resistance in plasma)&#xD;
&#xD;
          -  Language other than English as the main language of oral and written communication&#xD;
&#xD;
          -  Inability to provide informed consent or assent with a legal surrogate to sign consent&#xD;
&#xD;
          -  Major recent head injury, stroke, or major confounding cognitive factors including:&#xD;
&#xD;
               -  Cognitive impairment caused primarily by alcohol or substance use&#xD;
&#xD;
               -  Current active use of methamphetamine, cocaine or illicit use of narcotics&#xD;
                  (determined at screening and enrollment visits via clinical interview of&#xD;
                  substance abuse and dependence criteria)&#xD;
&#xD;
               -  MRI demonstrating current or past CNS lesions deemed to be clinically significant&#xD;
                  including that from past opportunistic infections but excluding white matter&#xD;
                  injury, as can be seen with cerebrovascular disease&#xD;
&#xD;
               -  Active brain infection, except for HIV&#xD;
&#xD;
               -  Significant systemic medical illness such as cancer requiring chemotherapy or&#xD;
                  end-stage cardiac or renal insufficiency&#xD;
&#xD;
          -  Unstable psychiatric condition (e.g. active psychosis, suicidal ideation, homicidal&#xD;
             ideation) or mental health or medical condition that, in the opinion of the&#xD;
             investigators, will make it difficult for the potential participant to participate in&#xD;
             the intervention&#xD;
&#xD;
          -  Cases where the investigators feel the participant won't be able to complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor Valcour, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Judith Moskowitz, PhD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Memory and Aging Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007 Sep 12;21(14):1915-21.</citation>
    <PMID>17721099</PMID>
  </reference>
  <reference>
    <citation>Kanmogne GD, Kuate CT, Cysique LA, Fonsah JY, Eta S, Doh R, Njamnshi DM, Nchindap E, Franklin DR Jr, Ellis RJ, McCutchan JA, Binam F, Mbanya D, Heaton RK, Njamnshi AK. HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon. BMC Neurol. 2010 Jul 13;10:60. doi: 10.1186/1471-2377-10-60.</citation>
    <PMID>20626870</PMID>
  </reference>
  <reference>
    <citation>Valcour V, Shikuma C, Shiramizu B, Watters M, Poff P, Selnes O, Holck P, Grove J, Sacktor N. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology. 2004 Sep 14;63(5):822-7.</citation>
    <PMID>15365130</PMID>
  </reference>
  <reference>
    <citation>Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, Vlassi C, Giulianelli M, Galgani S, Antinori A, Narciso P. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):174-82.</citation>
    <PMID>17356465</PMID>
  </reference>
  <reference>
    <citation>Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002 Apr;8(2):136-42.</citation>
    <PMID>11935465</PMID>
  </reference>
  <reference>
    <citation>Cysique LA, Brew BJ. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev. 2009 Jun;19(2):169-85. doi: 10.1007/s11065-009-9092-3. Epub 2009 May 9. Review.</citation>
    <PMID>19424802</PMID>
  </reference>
  <reference>
    <citation>Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology. 2006 May 9;66(9):1447-50.</citation>
    <PMID>16682686</PMID>
  </reference>
  <reference>
    <citation>Vance DE, Fazeli PL, Grant JS, Slater LZ, Raper JL. The role of neuroplasticity and cognitive reserve in aging with HIV: recommendations for cognitive protection and rehabilitation. J Neurosci Nurs. 2013 Oct;45(5):306-16. doi: 10.1097/JNN.0b013e31829d8b29.</citation>
    <PMID>24025470</PMID>
  </reference>
  <reference>
    <citation>Cohen-Katz J, Wiley S, Capuano T, Baker DM, Deitrick L, Shapiro S. The effects of mindfulness-based stress reduction on nurse stress and burnout: a qualitative and quantitative study, part III. Holist Nurs Pract. 2005 Mar-Apr;19(2):78-86.</citation>
    <PMID>15871591</PMID>
  </reference>
  <reference>
    <citation>Moynihan JA, Chapman BP, Klorman R, Krasner MS, Duberstein PR, Brown KW, Talbot NL. Mindfulness-based stress reduction for older adults: effects on executive function, frontal alpha asymmetry and immune function. Neuropsychobiology. 2013;68(1):34-43. doi: 10.1159/000350949. Epub 2013 Jun 15.</citation>
    <PMID>23774986</PMID>
  </reference>
  <reference>
    <citation>Gayner B, Esplen MJ, DeRoche P, Wong J, Bishop S, Kavanagh L, Butler K. A randomized controlled trial of mindfulness-based stress reduction to manage affective symptoms and improve quality of life in gay men living with HIV. J Behav Med. 2012 Jun;35(3):272-85. doi: 10.1007/s10865-011-9350-8. Epub 2011 May 20.</citation>
    <PMID>21597980</PMID>
  </reference>
  <reference>
    <citation>Lau MA, Bishop SR, Segal ZV, Buis T, Anderson ND, Carlson L, Shapiro S, Carmody J, Abbey S, Devins G. The Toronto Mindfulness Scale: development and validation. J Clin Psychol. 2006 Dec;62(12):1445-67.</citation>
    <PMID>17019673</PMID>
  </reference>
  <reference>
    <citation>Carmody J, Baer RA. Relationships between mindfulness practice and levels of mindfulness, medical and psychological symptoms and well-being in a mindfulness-based stress reduction program. J Behav Med. 2008 Feb;31(1):23-33. Epub 2007 Sep 25.</citation>
    <PMID>17899351</PMID>
  </reference>
  <reference>
    <citation>Jain S, Shapiro SL, Swanick S, Roesch SC, Mills PJ, Bell I, Schwartz GE. A randomized controlled trial of mindfulness meditation versus relaxation training: effects on distress, positive states of mind, rumination, and distraction. Ann Behav Med. 2007 Feb;33(1):11-21.</citation>
    <PMID>17291166</PMID>
  </reference>
  <reference>
    <citation>Shapiro SL, Oman D, Thoresen CE, Plante TG, Flinders T. Cultivating mindfulness: effects on well-being. J Clin Psychol. 2008 Jul;64(7):840-62. doi: 10.1002/jclp.20491.</citation>
    <PMID>18484600</PMID>
  </reference>
  <reference>
    <citation>Cohen-Katz J, Wiley SD, Capuano T, Baker DM, Kimmel S, Shapiro S. The effects of mindfulness-based stress reduction on nurse stress and burnout, Part II: A quantitative and qualitative study. Holist Nurs Pract. 2005 Jan-Feb;19(1):26-35. Erratum in: Holist Nurs Pract. 2005 Mar-Apr;19(2):78. Kimmel, Sharon [added].</citation>
    <PMID>15736727</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

